New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors
Publikation: Patent
There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.
Originalsprog | Engelsk |
---|---|
IPC | C07K 16/ 30 A I |
Patentnummer | CN104768573 |
Land/Område | Danmark |
Prioritetsdato | 03/05/2013 |
Prioritetsnummer | WO2013DK50126 |
Status | Udgivet - 8 jul. 2015 |
ID: 178221226